Summary of Valerio Therapeutics Half-Year Report (2026)
Operational Update:
- InVimmune Launch: Valerio Therapeutics has operationalized InVimmune, a subsidiary focusing on innovative in vivo cell therapy, targeting oncology as its first indication.
- Financial Position: The company reported cash reserves of €656,000 as of June 30, 2026, sufficient to cover expenses for 12 months.
Key Milestone Announcements:
- Dr. Gilles Besin became the new CEO on July 1, 2026, succeeding Julien Miara, to steer the company’s focus on RNA-based therapies and enhanced targeted delivery.
- The company has enhanced its partnership strategy, entering significant agreements with external companies for collaborative research and development.
Financial Highlights:
- Turnover: €3,102,000 for the first half of 2026, up from €126,000 in the same period of 2025.
- Losses: Net loss reported at €2,361,000 compared to €208,000 the previous year.
- Capital Increase: In August 2026, Valerio raised approximately €40.25 million via share issuance.
Future Outlook:
The company anticipates substantial potential due to recent partnerships and the acquisition of Etherna Immunotherapies, reinforcing its platform capabilities in RNA therapy.
About Valerio Therapeutics:
A biotechnology firm listed on Euronext Growth Paris, Valerio specializes in RNA-based precision therapies and innovative delivery mechanisms.
Contact:
- Investor Relations Email: ir@valeriotx.com
- Phone: +33 (0) 1 45 58 95 10
For further information and detailed financial statements, please visit Valerio Therapeutics’ website.
